Edition:
United Kingdom

People: Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

8.89CAD
17 May 2019
Change (% chg)

$0.29 (+3.37%)
Prev Close
$8.60
Open
$8.54
Day's High
$8.92
Day's Low
$8.54
Volume
68,701
Avg. Vol
69,740
52-wk High
$10.47
52-wk Low
$6.61

Economides, Celia 

Ms. Celia Economides is Associate Vice President, Corporate Communications & Patient Advocacy of the Company. She has over 15 years of experience in the life sciences and biotech industries, spanning communications, finance, patient advocacy, marketing and clinical development. She most recently served as a Director in Global Medical Affairs at BioMarin Pharmaceutical, Inc., where she led both patient advocacy and competitive intelligence efforts focusing on Duchenne Muscular Dystrophy. Previously, she led IR & Corporate Communications at Prosensa, which was acquired by BioMarin in January 2015. Prior to joining Prosensa, Ms. Economides was Director of IR & Program Development at the Biotechnology Innovation Organization (BIO), where she was responsible for BIO's outreach to the investment community and working with emerging companies to improve their communications and partnering activities. She led the program development at BIO's annual investor and BD conferences and provided industry research used in BIO's policy and advocacy activities. Prior to BIO, Ms. Economides worked at a healthcare focused hedge fund and in financial services focusing on the biotech sector. She began her career working in research at Columbia University. She holds a Bachelor of Arts (BA) degree from McGill University and a Master's in Public Health (MPH) from Columbia University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --